POLE and cancer: As, in this study, all patients with POLE-mutated cancers are allocated without restrictions to the “favorable molecular risk group” with omission of vaginal brachytherapy and external pelvic beam radiotherapy, this trial is very likely to extend our knowledge on prognosis of POLE-mutated cancers at least in this prespecified subset of patients.